1. Notified bodies conduct pre-market evaluation of manufacturers and issue CE certifications, resulting in what is known as CE marking of medical devices. They are almost always private sector organizations. 2.154 A number of applicants expressed the hope that post-market surveillance would be compromised if recycled devices could not be traced.  JJM stated, for example, that the use of third-party assessments has the potential to save Australian medical device manufacturers and their customers a lot of time and money, and could offer a choice of compliance assessment avenues, as is the case in larger markets such as the European Union (EU).  2.95 Reforms to the regulatory framework for medical devices in October 2010: the discussion paper also responded to the htA 8c recommendation. Proposition 2B focused on increasing pre-market control of implantable medical devices. This proposal consisted of two parts: the first required a TGA compliance assessment for implantable medical devices with the highest risk (Class III/AIMD). and the second application needed for medical equipment, which must be selected for testing lower-risk implantable devices (Class IIb).  However, on September 23, 2011, the TGA announced that this proposal would continue to be considered and that further consultations would take place on an amended proposal.
 Australia is a promising market for medical device manufacturers, with a well-developed health system, a growing population and ever-increasing spending in the health sector. However, in order to develop on the fifth continent, medical devices must conduct a compliance assessment with a positive result. 2.58 COMITÉ believes that Recommendation 8c of the HTA Review should be implemented to increase the rigour of the regulatory assessment of high-risk medical devices. An appropriate level of evidence verification should be conducted over a reasonable period of time. COMITÉ also believes that clinical data requirements need to be defined. The committee notes the AOA`s recommendation for at least two years of clinical evidence. As part of its registration process, the TGA recognises the CE marking of an EU-designated body, including T-V SUD. Given the above, low-risk medical devices can, in most cases, be registered in the Australian market in just three months. The EU directives on active medical devices and implantable medical devices will be replaced by a new Regulation on Medical Devices (EU Regulation 2017/745).